Global Kinetics has launched the global randomized Treat-to-Target trial of its Personal KinetiGraph Parkinson's disease monitor. This comes a few days after the publication of a a clinical trial showing how monitoring Parkinson's symptoms with the device can lead to improvements in patients' therapy.

The market for spinal cord stimulation (SCS) systems, used for treating chronic debilitating pain, is expanding relentlessly, and companies like Abbott Laboratories, Medtronic, Boston Scientific and Nevro are all vying to gain more market share with their respective technologies. At this year's annual meeting of the North American Neuromodulation Society (NANS) in Las Vegas, physicians were presented with the latest clinical evidence backing these innovations. This article looks at the overall SCS market, discusses study findings presented at NANS and the latest innovations. It also provides insights from two established pain management specialists on factors they think will drive SCS technologies forward.

The Australian company Global Kinetics has developed the Personal KinetiGraph, which includes a wearable smartwatch and a cloud-based system for continuous monitoring of Parkinson's disease symptoms to help improve patient management. KinetiGraph is 510(k)-cleared and CE marked, but the APPRISE multi-center trial will test the system’s ability to improve outcomes. The company hopes to convince US payers to cover it.